drugset / Trial / NCT03416569

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

NCT03416569

NaSingle-groupOpen-labelBasic science

Summary

To test whether specific aspects of the attention-enhancing effects of nicotine may be mediated by down-stream activation of alpha1 adrenoceptors, the interaction of nicotine and the alpha1 adrenergic antagonist prazosin on cognitive task performance will be tested in human non-smokers. The effects of a low-dose nicotine patch vs. a placebo patch will be tested in the presence and absence of prazosin over 4 test sessions.

Timeline

Start
2018-03
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotine Unknown 7 mg Topical
Subject Prazosin Unknown 1 mg Oral

Indications

No indication recorded.